Strand Therapeutics

Strand engineers mRNA circuits that sense biological conditions and release therapeutic payloads in targeted cells. Its first programs focus on cancer.

More selective activation could reduce exposure in healthy tissue.

• ?Safety and efficacy still need to be proven in patients.
• ?Delivery and manufacturing remain difficult for RNA medicines.
• ?Cancer drug development is crowded and expensive.

This catalog began with Core Memory coverage. The reporting is context, not an endorsement or investment recommendation.

Facts checked 2026-08-13. Company information comes from the public sources below. The company has not reviewed or endorsed it.